8-K current report · filed Aug 6, 2026

Astrana Health, Inc. (ASTH) 8-K Current Report: August 6, 2026

Item EX-99.1Item EX-99.2Item 2.02Item 7.01ASTH overview

Short answer

Astrana Health, Inc. (ASTH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.

Astrana Health, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the detailed results investors should review
  • Earnings disclosure may affect valuation, expectations, and near-term trading in ASTH shares

Item 7.01 · Regulation FD Disclosure

  • Conference call and webcast scheduled for August 6, 2026 at 2:30 p.m. Pacific Time
  • Discussion covers financial results for the three and six months ended June 30, 2026
  • Earnings presentation available through Astrana Health’s investor relations page, providing supplemental results context

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $972.5M, up 49%; net income attributable to Astrana $19.7M, up 109%
  • Adjusted EBITDA $68.9M, up 43%; adjusted diluted EPS $0.80, up 45%, with 7% adjusted EBITDA margin
  • Six-month operating cash flow $100.8M and free cash flow $92.9M, supporting investment and deleveraging capacity
  • 2026 adjusted EBITDA guidance raised to $255M-$280M; revenue guidance reaffirmed at $3.8B-$4.1B
  • Texas agreement adds approximately 3,000 Medicare Advantage professional-risk lives; affiliated ACOs generated $120.4M gross shared savings

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $972.5M, up 49% year over year, with Care Partners contributing $932.8M
  • Adjusted EBITDA $68.9M, up 43%, while adjusted EPS rose to $0.80 from $0.55
  • FY2026 adjusted EBITDA guidance raised to $255M-$280M, signaling confidence in broad-based operating outperformance
  • FY2026 revenue guidance remains $3.8B-$4.1B, while free cash flow guidance remains $105M-$132.5M
  • Full-risk arrangements generated 81% of Q2 capitation revenue, supporting stronger alignment but increasing medical-cost exposure

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Astrana Health, Inc. 8-K filings

Get the next ASTH 8-K as it lands

Follow ASTH for push alerts, or ask the research agent what this filing means.